*Johnson & Johnson: 3Q Innovative Medicine Operational Sales Growth Partially Offset by Impact From Stelara, Simponi/Simponi Aria, Remicade, Opsumit/Opsynvi and Imbruvica >JNJ

Dow Jones · 4d ago

Please log in to view news